ASTH — Astrana Health, Inc.

Summary of Astrana Health Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenues: $956 million, representing a 100% year-over-year increase and a 46% sequential increase, driven by the acquisition of Prospect Health and organic growth.
• Adjusted EBITDA: $68.5 million, up 52% year-over-year and 42% sequentially.
• Medical Cost Trends: Remained stable, with Medicare costs trending favorably below the 4.5% expectation and Medicaid costs showing improvement from Q2.
• Cash Position: Approximately $463 million in cash and short-term investments; net debt of $624 million, with a net leverage ratio of about 2.5x on a pro forma trailing 12-month adjusted EBITDA basis.

2. Strategic Updates and Business Highlights

• Acquisition of Prospect Health: Successfully integrated into Astrana's operations, with a focus on enhancing provider and patient experiences, standardizing systems, and implementing the Astrana technology platform.
• AI-Enabled Technology: Advancements in AI tools to improve patient care and operational efficiency, including predictive models for patient risk and automated claims analytics.
• New Partnerships: Expanded collaboration with Intermountain Health in Nevada and onboarded a new provider group in Southern California, enhancing Astrana's market presence and care delivery capabilities.

3. Forward Guidance and Outlook

• 2025 Revenue Guidance: Updated to a range of $3.1 billion to $3.18 billion, reflecting timing shifts in transitioning several payer contracts from partial to full risk, now expected in Q1 2026.
• Adjusted EBITDA Guidance: Revised to a range of $200 million to $210 million.
• 2026 Outlook: Anticipates tailwinds from improved Medicare Advantage rates and realization of synergies from the Prospect acquisition, but also foresees headwinds in Medicaid and exchange businesses due to regulatory changes.

4. Bad News, Challenges, or Points of Concern

• Delay in Full Risk Contracts: Transition to full risk arrangements has been postponed to Q1 2026, impacting revenue and EBITDA guidance.
• Medicaid Challenges: Potential headwinds from evolving regulatory dynamics could pressure membership and rates, particularly in California.
• Market Uncertainties: The company is navigating a complex regulatory environment, which may affect future performance, especially in Medicaid and exchange segments.

5. Notable Q&A Insights

• Revenue Guidance Clarification: The revenue and EBITDA reductions are strictly due to timing issues related to full risk contracts, not underlying performance changes.
• Medicaid Trends: Disenrollment rates in Medicaid are being monitored closely, with current attrition rates in the mid- to high single digits, which is better than anticipated.
• Partnership Economics: The new partnership with Intermountain Health is expected to enhance care coordination and potentially open avenues for expansion into additional states.
• Cost Trends: The company maintains confidence in managing medical costs effectively, with no negative prior period developments reported.

Overall, Astrana Health demonstrated robust financial growth in Q3 2025, driven by strategic acquisitions and partnerships, while also addressing challenges related to regulatory changes and contract transitions. The company remains optimistic about future growth despite some headwinds.